Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Engelman

Showing results (1-10 of 189) with videos related to

Pageof 19
Sort By:
Nature Reviews. Cancer|July 25, 2009
Targeting PI3K signalling in cancer: opportunities, challenges and limitationsJeffrey A Engelman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancerJeffrey A Engelman
Cancer Cell|October 15, 2014
The double life of p85Carlotta Costa, Jeffrey A Engelman
Current Opinion in Genetics & Development|March 8, 2008
Acquired resistance to tyrosine kinase inhibitors during cancer therapyJeffrey A Engelman, Jeffrey Settleman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2010
PIKing the right patientAlexa B Turke, Jeffrey A Engelman
Seminars in Respiratory and Critical Care Medicine|July 30, 2005
Factors predicting response to EGFR tyrosine kinase inhibitorsJeffrey A Engelman, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerJeffrey A Engelman, Pasi A Jänne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
ALK in lung cancer: past, present, and futureAlice T Shaw, Jeffrey A Engelman
The New England Journal of Medicine|June 26, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Jeffrey A Engelman
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2010
Chemoprevention meets glucose controlJeffrey A Engelman, Lewis C Cantley
Pageof 19

Showing results (1-10 of 189) with videos related to

Sort By:
Pageof 19
Nature Reviews. Cancer|July 25, 2009
Targeting PI3K signalling in cancer: opportunities, challenges and limitationsJeffrey A Engelman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancerJeffrey A Engelman
Cancer Cell|October 15, 2014
The double life of p85Carlotta Costa, Jeffrey A Engelman
Current Opinion in Genetics & Development|March 8, 2008
Acquired resistance to tyrosine kinase inhibitors during cancer therapyJeffrey A Engelman, Jeffrey Settleman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2010
PIKing the right patientAlexa B Turke, Jeffrey A Engelman
Seminars in Respiratory and Critical Care Medicine|July 30, 2005
Factors predicting response to EGFR tyrosine kinase inhibitorsJeffrey A Engelman, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerJeffrey A Engelman, Pasi A Jänne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
ALK in lung cancer: past, present, and futureAlice T Shaw, Jeffrey A Engelman
The New England Journal of Medicine|June 26, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Jeffrey A Engelman
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2010
Chemoprevention meets glucose controlJeffrey A Engelman, Lewis C Cantley
Pageof 19